Ionis Pharmaceuticals Inc
IONS
Market Cap$6.8B
Close$
$-22.58
138.1% downside
Current Fair Value
138.1% downsideOvervalued by 138.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.80 Billion |
|---|---|
| Enterprise Value | $5.44 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.04 |
| Beta | 0.25 |
| Outstanding Shares | 159,137,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -25.3 |
|---|---|
| PEG | 8.79 |
| Price to Sales | 0.07 |
| Price to Book Ratio | 19.78 |
| Enterprise Value to Revenue | 0.04 |
| Enterprise Value to EBIT | -0.04 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 1.47 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...